Page 3 - Geant4 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Geant4. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Geant4 Today - Breaking & Trending Today
Abstract Background: Geant4 is a Monte Carlo code extensively used in medical physics for a wide range of applications, such as dosimetry, micro- and nanodosimetry, imaging, radiation protection, and nuclear medicine. Geant4 is continuously evolving, so it is crucial to have a system that benchmarks this Monte Carlo code for medical physics against reference data and to perform regression testing. Aims: To respond to these needs, we developed G4-Med, a benchmarking and regression testing system of Geant4 for medical physics. Materials and Methods: G4-Med currently includes 18 tests. They range from the benchmarking of fundamental physics quantities to the testing of Monte Carlo simulation setups typical of medical physics applications. Both electromagnetic and hadronic physics processes and models within the prebuilt Geant4 physics lists are tested. The tests included in G4-Med are executed on the CERN computing infrastructure via the use of the geant-val web application, deve ....
Abstract Particle therapy is a radiotherapy modality in which accelerated protons or heavier ions are used to deliver a therapeutic dose to a treatment region. There are several advantages to using particle therapy over conventional photon therapy, including higher dose conformity, a higher relative biological effectiveness and increased healthy tissue sparing (particularly in the region behind the target). Due to the high dose conformity, large dose gradients will be present at the boundary between the treatment region and surrounding healthy tissue. Therefore, improvements in quality assurance techniques and development of methods to further improve the target-selectivity of particle therapy are two of the most important opportunities for enhancing the delivery of particle therapy. ....